Please assess the completion status of the following clinical trial:

Trial Title: Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women with T scores less than -2.5 (groups A and C)~* The periodontitis patients were selected based on the radiographical evidence of bone loss, presence of four or more sites with bleeding on probing (BOP), ≥5 mm pocket depth (PD) and ≥6 mm clinical attachment loss (CAL).~* The clinically healthy control groups were selected on the basis of no radiographic bone loss or CAL and PD≤3 mm.~Exclusion Criteria:~* Any known systemic disease rather than osteoporosis~* Smoking~* Antibiotic therapy within the last 3 months~* Periodontal treatment in the last 6 months

- Gender: FEMALE
- Minimum Age: 51 Years
- Maximum Age: 66 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): * Subjects with chronic periodontitis and osteoporosis.~* Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.
- Group B (Type: ACTIVE_COMPARATOR): * Subjects with chronic periodontitis and systemically healthy.~* Phase 1 periodontal theraphy was administered to the subjects.
- Group C (Type: ACTIVE_COMPARATOR): * Subjects with periodontally healthy and osteoporosis.~* Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects.
- Group D (Type: NO_INTERVENTION): * Systemically and periodontally healthy controls~* No intervention has been made.

Based on this trial design, predict the completion outcome and termination type (if applicable).